anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method is provided for the identification of a compound which affects mRNA  stability, in particular induces mRNA degradation, in which a DNA expression system which in the absence of test compound is capable of expressing a protein having a detectable signal, wherein the mRNA which codes for the protein and which is transcribed from the expression system comprises at least one copy of a mRNA instability sequence, is contacted with a test compound and the detectable signal is measured in the presence of the test compound and compared with a control. The method may be used to identify compounds which induce degradation of mRNA, e.g. cytokine (e.g. IL-1.beta.) mRNA, which when inappropriately stabilised can give rise to diseases or medical conditions, e.g. cytokine induced inflammatory disease.
FIELD: medicine, pharmacy. SUBSTANCE: pharmaceutical composition of human calcitonin gene peptide has liposomes made of natural soybean phospholipid in the weight ratio of human calcitonin gene peptide to phospholipid = (1-2):(100-8000). Half-life value for composition is above 72 h. Composition can be administrated by intravenous route, by mucusa mouth and nose spraying in the dose 0.1-10 pg of human calcitonin gene peptide/kg of body mass for treatment of patients with hypertension and congested cardiac insufficiency. Biological availability of composition is about 80%. Invention provides effective prophylaxis and treatment of cardiovascular diseases. EFFECT: enhanced effectiveness, prolonged stability of composition. 8 cl, 8 tbl, 3 ex
The invention discloses an injection for treating pyrexia and the hoof disease of dairy cows, and its preparation method, and belongs to the technical field of veterinary western medicines. Every 100 ml of the injection is composed of 2-10g of diclofenac sodium, 0.1-0.5g of an antioxidant, 0.01-0.05g of a stabilizer, 20-80 ml of a cosolvent, and the balance of water for injection. The injection meets the veterinary drug market's demands on new antipyretic analgesic drugs, and has the advantages of good curative effect, small side effects and no accumulation in the clinical use process. Propylene glycol or polyethylene glycol-400 adopted as a cosolvent and the stabilizer disodium ethylenediaminetetraacetate synergistically enhance the dissolvability of diclofenac sodium in water, so the stability of the injection is increased. Anhydrous sodium sulfite has a stable anti-oxidation effect in alkaline environment with the pH value of 7.5-9.0. The preparation method of the diclofenac sodium injection has the advantages of simple and convenient preparation, low production cost, and suitableness for large-scale industrial production.
Cross talk between T cells and airway smooth muscle (ASM) may play a role in modulating asthmatic airway inflammation and remodeling. Infiltrating T cells have been observed within the ASM bundles of asthmatics, and a wide range of direct and indirect interactions between T cells and ASM has been demonstrated using various in vitro and in vivo model systems. Contact-dependent mechanisms such as ligation and activation of cellular adhesion and costimulatory molecules, as well as the formation of lymphocyte-derived membrane conduits, facilitate the adhesion, bidirectional communication, and transfer of materials between T and ASM cells. T cell-derived cytokines, particularly of the Th1, Th2, and Th17 subsets, modulate the secretome, proliferation, and contractility of ASM cells. This review summarizes the mechanisms governing T cell-ASM cross talk in the context of asthma. Understanding the underlying mechanistic basis is important for directing future research and developing therapeutic interventions targeted toward this complex interaction.
The invention relates to a Funing expandable vaginal suppository. The expandable suppository comprises a curcuma rhizome extract, a traditional Chinese medicine composition, a matrix and an expansion carrier. The curcuma rhizome extract, the traditional Chinese medicine composition and the matrix form a drug-containing matrix, which is coated on the surface of the carrier. The traditional Chinese medicine composition is prepared from sophora flavescens, Radix Astragali and phellodendron. The curcuma rhizome extract and the traditional Chinese medicine composition are respectively prepared into microballoons to improve the solubility and stability of curcuma rhizome extract and the traditional Chinese medicine composition and increase bioavailability of the suppository. The Funing expandable vaginal suppository employs six unique technologies, and has beneficial effects of prevention of outflow liquid, high stability, lasting curative effect and prevention of secondary infection.
BACKGROUND: Hair loss occurs due to various biological and environmental causes, which can have psychosocial consequences. The Wnt/β-catenin signaling is well-known for its role in hair growth and regeneration, as it induces the proliferation and differentiation of hair cells. When the leucine-rich G protein-coupled receptor 5 (Lgr5) interacts with the R-spondins, the frizzled receptor (FZD), a Wnt receptor, becomes stabilized, resulting in an increased β-catenin activity.
AIM: We investigated whether the octapeptide that binds to Lgr5 enhances proliferation and differentiation of human primary hair cells through the activation of Wnt/β-catenin signaling.
METHODS: The binding affinity of the octapeptide to Lgr5 was evaluated using surface plasmon resonance (SPR). We confirmed changes in proliferation and related factors like β-catenin activation and growth factors (GFs) expression in human hair follicle dermal papilla cells (HHFDPCs). Additionally, we observed the proliferation and the expression of differentiation markers in human hair follicle outer root sheath cells (HHFORSCs), human hair follicle germinal matrix cells (HHFGMCs), and human hair follicle stem cells (HHFSCs). We used three-dimensional HHFDPC spheroid culture treated with dihydrotestosterone (DHT) to create in vitro conditions that mimic androgenetic alopecia, and we studied the effects of octapeptide on Wnt expression and HHFSC differentiation.
RESULTS: The binding of the octapeptide to Lgr5 was confirmed using SPR analysis. In HHFDPCs, treatment with octapeptide resulted in a concentration-dependent increase in proliferation. We also observed increased nuclear translocation of β-catenin and increased expression of its downstream targets. HHFDPCs treated with octapeptide exhibited increased expression of growth factors and phosphorylation of Akt and ERK. In addition, we confirmed that octapeptide increased proliferation and induced differentiation in HHFORSCs, HHFGMCs, and HHFSCs. Under the HHFDPC spheroid culture conditions, we found that octapeptide restored the inhibition of Wnt-5a and Wnt-10b expressions by DHT. In HHFSCs treated with HHFDPC spheroid culture media, we observed that octapeptide recovered the inhibition of differentiation by DHT.
CONCLUSION: We found that octapeptides activated the Wnt/β-catenin signaling and induced the proliferation and differentiation of human primary hair cells by acting as an exogenous ligand for Lgr5. In addition, octapeptides recovered inhibited hair regeneration characters by DHT in androgenetic alopecia-mimic in vitro model. These findings suggest that octapeptides may be a promising therapeutic option for treating hair loss.
Those randomized to the RT group will complete baseline and post-intervention assessments at weeks 0 and 12. For the intervention, they will complete resistance training for approximately 12 minutes 2x per week for 12 weeks.
A method for characterising a region of interest comprising adipose tissue using medical imaging data, e.g. based on computer tomography (CT) of a subject is disclosed. The method comprises calculating the value of a radiomic signature of the region of interest using the medical imaging data. Also disclosed is a method for deriving a radiomic signature indicative of adipose tissue dysfunction. The method comprises obtaining a radiomic dataset and using the radiomic dataset to construct a radiomic signature of a region of interest comprising adipose tissue. Also disclosed are systems for performing the aforementioned methods.
Cohort 2: Patients received 15 mg/kg as a 30 minute IV infusion once daily. BSI, HABP or VABP patients received plazomicin and any supplemental antibiotic therapy, according to Investigator's choice, for 7 to 14 days. cUTI or AP patients received plazomicin monotherapy only for 4 to 7 days with an option to switch to oral therapy on or after Day 5.
The invention provides a phototoxicity experiment detection device which comprises a lightproof experimental bin body. The lightproof experimental bin body is internally provided with a plurality of uviol lamps with UVA of single wavelength of 365nm as an experimental light source and a plurality of small animals fixing brackets. The front face of the experimental bin body is provided with movable observation windows on which glass capable of filtering ultraviolet waves is arranged. A sterilizer, a ventilation installation and a temperature and humidity controller are arranged in the experimental bin body to enable the environment in the bin body to meet experiment requirement. The experimental bin body is internally provided with an ultraviolet irradiation detector for detecting the intensity of the experiment light source. With the computer control of the experimental process, experimental data can be stored in a computer or experiment reports are printed through a printer. The invention has the advantages that the injury reaction of chemical substances to a human body exposed in ultraviolet irradiation is detected; the light intensity and irradiation time can be controlled, the interference of stray light is less, the experimental efficiency is high, the experimental environment is safe, and the experimental data is accurate.
In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments, the treatment includes a semisolid hydrogel embedded with liposomes. The liposomes can contain an effector molecule or molecules. When phagocytic cells such as monocytes infiltrate the hydrogel, they encounter the liposomes and incorporate the liposomes carrying the effector molecules into the cells. In some embodiments, the effector molecules can induce angiogenesis. The matrix can contain other effector molecules designed to attract specific cells to the matrix. The cells can also remain in the matrix and secret molecules such as proteins and hormones that will diffuse through the matrix material to the surrounding tissue.
This application concerns novel methods which enable or improve the ability of molecules, particularly large molecules, to cross the blood-brain barrier, the blood-eye barrier, and/or the blood-nerve barrier and therefore be of improved diagnostic and/or therapeutic use in humans and other mammals. These methods involve perispinal administration of imaging agents without direct intrathecal injection. Perispinal administration is defined as administration of the molecule into the anatomic area within 10 cm of the spine. Perispinal administration results in absorption of the imaging agent into the vertebral venous system. The vertebral venous system is capable of transporting molecules into the brain, the eye, the retina, the auditory apparatus, the cranial nerves, the head, the spine, the spinal cord, the vertebral bodies, the dorsal root ganglia, and the nerve roots via retrograde venous flow, thereby bypassing the blood-brain barrier and similar barriers and delivering the molecules to the brain, the eye, the retina, the auditory apparatus, the cranial nerves, the head, the spine (including the vertebral bodies), the spinal cord, the dorsal root ganglia, or the nerve roots. This method may be utilized for a wide variety of diagnostic agents, including, but not limited to biologics, monoclonal antibodies, fusion proteins, monoclonal antibody fragments, antibodies to tumor antigens, hormones, cytokines, anti-cytokines, interleukins, anti-interleukins, interferons, colony-stimulating factors, cancer chemotherapeutic agents, growth factors, anti-virals and antibiotics, including those which are radiolabeled, iodinated, or otherwise altered to facilitate diagnostic imaging. Included in these novel methods are perispinal delivery of amyloid imaging agents, and other ligands radiolabeled with [11C] or [18F] to faciliate PET imaging of the brain.
OBJECTIVES: Predicting the need for surgical treatment among patients with chronic rhinosinusitis (CRS) is challenging. The delta neutrophil index (DNI) has been proposed as a useful laboratory marker of immature granulocytes, which indicates infection or severe inflammation in several diseases. This study evaluated DNI as an early predictor of the need for surgery in patients with CRS.
METHODS: A total of 117 patients diagnosed with CRS were enrolled in this retrospective and observational study. Medical records, including symptoms data, WBC count, ESR level, LUC count, Lund-Mackay scores, and DNI, were reviewed. The receiver operating characteristic (ROC) curves were analyzed to determine the optimal cut-off values for predicting surgery.
RESULTS: Among 117 patients, 49 patients (41.9%) needed surgical intervention. The areas under the WBC, ESR, LUC, and DNI ROC curves were .571, .600, .592, and .782, respectively. The optimal cut-off value of DNI to predict surgery was .9%. The prognostic precision of DNI showed that the sensitivity was 59.2% and the specificity was 98.5%. In the analysis of risk factors, DNI levels were significantly associated with surgical intervention (odds ratio, 2.22; 95% confidence interval, 1.48-3.34; P < .01).
CONCLUSIONS: The level of DNI, which reflects the severity of the disease, may be a useful predictor for determining the need for surgical intervention in patients with CRS. This is the first literature to verify the role of DNI in upper airway disease.
Research ethics review committees (ERCs) worldwide faced daunting challenges during the COVID-19 pandemic. There was a need to balance rapid turnaround with rigorous evaluation of high-risk research protocols in the context of considerable uncertainty. This study explored the experiences and performance of ERCs during the pandemic. We conducted an anonymous, cross-sectional, global online survey of chairs (or their delegates) of ERCs who were involved in the review of COVID-19-related research protocols after March 2020. The survey ran from October 2022 to February 2023 and consisted of 50 items, with opportunities for descriptive responses to open-ended questions. Two hundred and three participants [130 from high-income countries (HICs) and 73 from low- and middle-income countries (LMICs)] completed our survey. Respondents came from diverse entities and organizations from 48 countries (19 HICs and 29 LMICs) in all World Health Organization regions. Responses show little of the increased global funding for COVID-19 research was allotted to the operation of ERCs. Few ERCs had pre-existing internal policies to address operation during public health emergencies, but almost half used existing guidelines. Most ERCs modified existing procedures or designed and implemented new ones but had not evaluated the success of these changes. Participants overwhelmingly endorsed permanently implementing several of them. Few ERCs added new members but non-member experts were consulted; quorum was generally achieved. Collaboration among ERCs was infrequent, but reviews conducted by external ERCs were recognized and validated. Review volume increased during the pandemic, with COVID-19-related studies being prioritized. Most protocol reviews were reported as taking less than three weeks. One-third of respondents reported external pressure on their ERCs from different stakeholders to approve or reject specific COVID-19-related protocols. ERC members faced significant challenges to keep their committees functioning during the pandemic. Our findings can inform ERC approaches towards future public health emergencies. To our knowledge, this is the first international, COVID-19-related study of its kind.
In recent years, with advances in methods of neonatal resuscitation and caring methods, the survival rate of preterm infants has gradually increased. Sucking, swallow and respiratory dysfunction are widespread complications in the preterm infants that reason oral feeding difficulties. Safe and successful oral feeding requires proper maturation of sucking, swallowing, and respiration. The development of behaviors necessary for safe and successful nutrition begins long before birth. Jaw movements begin to be seen in the intrauterine 11th week. But sucking-swallowing-respiratory coordination is not sufficiently developed before 34 weeks of gestation. For this reason, preterm babies at the greater gestational week usually show more developed and consistent feeding skills. Maternal breast milk is best for neurodevelopment in preterm infants. Achieve oral feeding and maternal breast milk as early as possible is beneficial for preterm infants.

Oral motor stimulation (OMS) is defined as the sensorial stimulation of cheek, lip, jaw, upper-lower gum, internal cheek, tongue and soft palate that affects the physiology of oropharyngeal mechanisms and develops feeding functions. OMS used as an alternative or supplementary early intervention strategy to develop oral feeding skills in preterm infants. Previous studies have indicated that the use of OMS during or before the transition to oral feeding may not only have positive effects on the preterm infants' feeding behaviors but also enhance their general clinical course. Preterm infants who suffer from oral feeding problems often experience longterm health problems and delayed discharge from the hospital. A more effective feeding decreases adverse outcomes by decreasing hospital stays.

Preterm infants are required to prolonged NICU stay in order to stabilized, feeding, and gain optimal weight. Increasing prematurity and reduced birth weight lead to extensive resource utilization. In addition all nutritional options except breast milk increase the cost. OMS can develop sucking success and provide early oral feeding. Thus nurse labor and hospital costs may decrease and OMS can be a cost-effective application.

,
Systems and methods may present exercises to a user using a mobile device communicatively coupled to a wearable device. The system and method may modify the treatment calendar based on, for example, information determined from the workout (e.g., repetition of the completion, duration of the completion, video, etc.), feedback from the user, etc. A method may include receiving a control command from a wearable device communicatively coupled to a mobile device, the control command causing the mobile device to take an action related to an exercise. The treatment calendar may be automatically modified, for example, in response to determining the number of repetitions or duration of the workout. The modified treatment calendar may be presented on a user interface (e.g., on a display of the wearable device or the mobile device).
OBJECTIVES: I. Determine the complete response rate to 2 courses of paclitaxel and topotecan followed by consolidation chemoradiotherapy in patients with limited stage small cell lung cancer. II. Determine the toxic effects of this regimen in this patient population. III. Describe the pattern of relapse, documenting carefully the location of relapse with respect to the original disease volume and the radiation treatment field in these patients. IV. Determine the overall and failure free survival of these patients.

OUTLINE: Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 1. Filgrastim (G-CSF) is administered subcutaneously every day starting on day 6 until blood counts recover. The course is repeated once beginning on day 22. After restaging, patients begin thoracic radiotherapy daily, five days per week, for 6-7 weeks. On the same day that radiotherapy begins, patients receive carboplatin IV over 1 hour (day 43) and etoposide IV over 1 hour daily for 3 days (days 43-45). The consolidation chemotherapy is repeated every 21 days for a total of 3 courses. Patients with stable or responding disease undergo prophylactic cranial irradiation. Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then at least every year.

PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study within 15-18 months.
To investigate the risk factors for new renal scarring (NRS) in children with vesicoureteral reflux (VUR) receiving continuous antibiotic prophylaxis (CAP). This was a single-center cohort study. The clinical data of 140 children with grade I-V VUR receiving CAP were analyzed. In this study, exposure variables were sex, younger age at the initial diagnosis of UTI ≤ 12 months, the occurrence of breakthrough urinary tract infection (BT-UTI), high-grade VUR, bilateral VUR, etiology, presence of renal scarring at the initial diagnosis and ultrasound abnormalities. The outcome was NRS. A total of 140 children were included in the risk factor analysis of NRS, 73 of whom experienced NRS, an incidence rate of 52.14%. Multivariate Cox regression suggested that the presence of renal function impairment after the initial diagnosis of UTI (OR 3.411, 95% CI 1.5751-6.646) and the occurrence of BT-UTI while receiving CAP (OR 1.995, 95% CI 1.089-2.958) were independent risk factors for NRS. Multivariate Cox regression showed that high-grade VUR had no significant effects on NRS (OR 0.940, 95% CI 0.462-1.912, P = 0.864). No significant difference was identified in multivariate Cox regression analysis in the IV-V group (vs I-III group) (OR 0.960, 95% CI 0.565-1.633, P = 0.960). Renal function impairment after the initial diagnosis of UTI and the occurrence of BT-UTI while receiving CAP were independent risk factors for NRS. Neither univariate analysis nor multivariate analysis found a correlation between VUR grade and NRS.
Subjects in this arm will receive standard of care treatment with no intervention. They will receive month 6 follow up.
The invention discloses a dahurian angelica root drug mellow distilling liquid effective constituent group finger print and buildup method and the application. The method includes the distilling of dahurian angelica root drug and the buildup of mellow distilling liquid effective constituent group finger print and gaining the dahurian angelica root drug mellow distilling liquid effective constituent group finger print. It separates finger print to three area, II area and III area is the main effective constituent group. The II area is mainly relative to fever allaying, anti-inflammation, antiendotoxin, and the III area is mainly relative to ease pain and excitement allaying function. The finger print has high repeatability and good stability. It could be used to test the chemical constituent in dahurian angelica root, and also could be used as the identification and quantity control method, and could develop new drugs from the effective constituents in distilling liquid.